Preparation of radiolabeled erlotinib analogues and analysis of the effect of linkers
Authors:
- 21 September 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 76, 128995
Abstract
No abstract availableKeywords
Funding Information
- Department of Atomic Energy, Government of India
- Bhabha Atomic Research Centre
This publication has 19 references indexed in Scilit:
- PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PETDrug Discovery Today, 2012
- Erlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansTherapeutic Advances in Medical Oncology, 2011
- Radiolabeled Small Molecule Protein Kinase Inhibitors for Imaging with PET or SPECTMolecules, 2010
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor XenograftsCancer Research, 2009
- The effect of the [F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety—An EGFR putative irreversible inhibitorApplied Radiation and Isotopes, 2007
- FDA Drug Approval Summary: Erlotinib (Tarceva®) TabletsThe Oncologist, 2005
- Epidermal growth factor receptor inhibition strategies in oncologyEndocrine-Related Cancer, 2004
- The EGFR family and its ligands in human cancerEuropean Journal of Cancer, 2001
- The EGF receptor family as targets for cancer therapyOncogene, 2000